We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 21, 2021

Delayed Immune-Related Adverse Events With Anti–PD-1–Based Immunotherapy in Melanoma

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Delayed Immune-Related Adverse Events With Anti–PD1-Based Immunotherapy in Melanoma
Ann. Oncol 2021 Mar 30;[EPub Ahead of Print], CN Owen, X Bai, T Quah, SN Lo, C Allayous, S Callaghan, C Martínez-Vila, R Wallace, P Bhave, I Reijers, N Thompson, V Vanella, C Gerard, S Aspeslagh, A Labianca, A Khattak, M Mandala, W Xu, B Neyns, O Michielin, CU Blank, SJ Welsh, A Haydon, S Sandhu, J Mangana, JL McQuade, PA Ascierto, L Zimmer, DB Johnson, A Arance, P Lorigan, C Lebbé, MS Carlino, R Sullivan, GV Long, AM Menzies

Further Reading